231 related articles for article (PubMed ID: 31618128)
1. Improving Adjuvant Endocrine Treatment Tailoring in Premenopausal Women With Hormone Receptor-Positive Breast Cancer.
Lambertini M; Blondeaux E; Perrone F; Del Mastro L
J Clin Oncol; 2020 Apr; 38(12):1258-1267. PubMed ID: 31618128
[No Abstract] [Full Text] [Related]
2. Options for Endocrine-Refractory, Hormone Receptor-Positive Breast Cancer: Which Target and When?
Borges VF
J Clin Oncol; 2021 Dec; 39(35):3890-3896. PubMed ID: 34709849
[No Abstract] [Full Text] [Related]
3. Is Estradiol Monitoring Necessary in Women Receiving Ovarian Suppression for Breast Cancer?
Papakonstantinou A; Foukakis T; Rodriguez-Wallberg KA; Bergh J
J Clin Oncol; 2016 May; 34(14):1573-9. PubMed ID: 26951320
[TBL] [Abstract][Full Text] [Related]
4. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
Sharma R; Hamilton A; Beith J
Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661
[TBL] [Abstract][Full Text] [Related]
5. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
Jankowitz RC; McGuire KP; Davidson NE
Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant Surgical Oophorectomy Plus Tamoxifen in Premenopausal Women With Operable Hormone Receptor-Positive Breast Cancer: A Global Treatment Option.
Love RR
Clin Breast Cancer; 2016 Aug; 16(4):233-7. PubMed ID: 27117241
[TBL] [Abstract][Full Text] [Related]
7. Can endocrine treatment for hormone-positive premenopausal women with early breast cancer replace adjuvant chemotherapy?
Malayeri R
J Clin Oncol; 2003 Jun; 21(12):2444-5; author reply 2446-7. PubMed ID: 12805348
[No Abstract] [Full Text] [Related]
8. Adjuvant endocrine therapy for premenopausal women with early breast cancer.
Bao T; Davidson NE
Breast Cancer Res; 2007; 9(6):115. PubMed ID: 18190722
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive early breast cancer: Evidence evaluation and GRADE recommendations by the Italian Association of Medical Oncology (AIOM).
Gori S; Puglisi F; Cinquini M; Pappagallo G; Frassoldati A; Biganzoli L; Cortesi L; Fiorentino A; Angiolini C; Tinterri C; De Censi A; Levaggi A; Del Mastro L
Eur J Cancer; 2018 Aug; 99():9-19. PubMed ID: 29886394
[TBL] [Abstract][Full Text] [Related]
10. Ovarian suppression/ablation in premenopausal ER-positive breast cancer patients. Issues and recommendations.
Pritchard KI
Oncology (Williston Park); 2009 Jan; 23(1):27-33. PubMed ID: 19283918
[TBL] [Abstract][Full Text] [Related]
11. Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases.
El-Saghir NS; El-Hajj II; Makarem JA; Otrock ZK
Anticancer Drugs; 2006 Sep; 17(8):999-1002. PubMed ID: 16940812
[TBL] [Abstract][Full Text] [Related]
12. Improving Outcomes for High-Risk Hormone Receptor-Positive Breast Cancer With CDK Inhibition.
Hicks D; O'Regan RM
J Clin Oncol; 2022 Apr; 40(11):1142-1146. PubMed ID: 35201844
[No Abstract] [Full Text] [Related]
13. Blocking the Cycle: Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic, Hormone Receptor-Positive Breast Cancer.
Wander SA; Mayer EL; Burstein HJ
J Clin Oncol; 2017 Sep; 35(25):2866-2870. PubMed ID: 28580881
[TBL] [Abstract][Full Text] [Related]
14. Maximizing the Clinical Benefit of Anthracyclines in Addition to Taxanes in the Adjuvant Treatment of Early Breast Cancer.
Curigliano G; Criscitiello C
J Clin Oncol; 2017 Aug; 35(23):2600-2603. PubMed ID: 28661760
[TBL] [Abstract][Full Text] [Related]
15. Multidisciplinary Management of Breast Cancer With Extensive Regional Nodal Involvement.
Smith BD; Goetz MP; Boughey JC
J Clin Oncol; 2020 Jul; 38(20):2290-2298. PubMed ID: 32442073
[No Abstract] [Full Text] [Related]
16. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian Breast and Colorectal Cancer Study Group Trial 5.
Jakesz R; Hausmaninger H; Kubista E; Gnant M; Menzel C; Bauernhofer T; Seifert M; Haider K; Mlineritsch B; Steindorfer P; Kwasny W; Fridrik M; Steger G; Wette V; Samonigg H;
J Clin Oncol; 2002 Dec; 20(24):4621-7. PubMed ID: 12488405
[TBL] [Abstract][Full Text] [Related]
17. Ovarian ablation for premenopausal breast cancer: A review of treatment considerations and the impact of premature menopause.
Nourmoussavi M; Pansegrau G; Popesku J; Hammond GL; Kwon JS; Carey MS
Cancer Treat Rev; 2017 Apr; 55():26-35. PubMed ID: 28288389
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant hormonal therapy for premenopausal women with breast cancer.
Brown RJ; Davidson NE
Semin Oncol; 2006 Dec; 33(6):657-63. PubMed ID: 17145345
[TBL] [Abstract][Full Text] [Related]
19. Late Recurrence Following Early Breast Cancer.
Thomas A; Parsons HA; Smith KL
J Clin Oncol; 2022 May; 40(13):1400-1406. PubMed ID: 35239445
[No Abstract] [Full Text] [Related]
20. Optimizing endocrine therapy for premenopausal and postmenopausal women with breast cancer.
Cianfrocca M; Wolff AC
Oncology (Williston Park); 2007 Jan; 21(1):63-9; discussion 69, 72, 75 passim. PubMed ID: 17313157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
